ACE inhibitors, 16, 97, 334, 351, 390; in Australia, 136, 139, 149; in Denmark, 263; in Israel, 370–71; in Japan, 169–70; in the U.S., 38, 49

ÄDEL-reform (Sweden), 208, 225

Advanced cardiac life support, 38, 98

Adverse selection problems, 346, 347

Age difference, 3, 21, 385, 394 (see also Elderly patients); in Israel, 382; in Italy, 332, 343; in Korea, 191; in the U.S., 31, 35

Alberta, AMI care in, 88–103; consequences of changes in, 99–102; expertise in, 98–99; financing of, 89–92, 100–102; health outcomes, 99–100; low-tech, 97–98; mortality and, 88, 99–100, 102–3; regulation and, 92–93; technological change in, 94–98

Alberta Acute Care Funding System, 91

Alberta Health Insurance System, 89

Alteplase. See Tissue plasminogen activator (tPA)

AMI (acute myocardial infarction), 16–17 (see also AMI care in specific country, Canadian province); recurrent, 42–45, 127, 136, 139, 145–46, 151, 222

Angina, 113, 130–32, 151, 220, 254, 261, 263; in Israel, 374, 381

Angiography, 48, 80, 98 (see also Cardiac catheterization); in Australia, 127–28, 130–32, 136, 146, 151; in England, 273, 277–79; in Finland, 238, 241; in Japan, 175; in Quebec, 76, 78; in Sweden, 210, 217

Angioplasty, 389, 390, 391–92 (see also PTCA); balloon, 293, 369, 381; in Canada, 76, 84–86, 102; in Finland, 238, 241–43; in France, 297; in the U.S., 14–15, 24, 38, 41, 48, 49, 50

Anticoagulants, 263, 281, 351. See also Streptokinase

Antiplatelet agents, 284, 302, 334, 351, 353; in Australia, 128, 136–39, 149, 151

Arrhythmias, 216, 374

Aspirin, 15, 16, 151, 170, 392; in Canada, 97–98, 113; in Europe, 220, 245, 281, 354; in Israel, 370; in Taiwan, 200; in the U.S., 36–38, 41, 48, 50

Australia, AMI care in, 11, 12, 121–53, 389; cardiac complications and, 139–43; consequences of changes in, 139–42; effects of incentives on, 146–52; high-tech, 126–36; hospitals in, 13, 121, 122–23; incentives for technological change in, 122–25; insurance in, 123; low-tech, 136–39; medical expenditures and, 142–46; MONICA Project in, 122–25, 139; mortality and, 127, 136, 139–42, 393; payment in, 18, 124; in Perth,
Australia (continued)
125–32; specialists in, 122, 123, 150; technological change in, 125–39; treatment rates in, 150; in Victoria, 132–36
Balloon angioplasty, 293, 369, 381
Belgium, AMI care in, 306–21; consequences of changes in, 314–18; effects of incentives on, 319–21; financing of, 307–8; high-tech, 310–13; incentives for technological change in, 307–9; low-tech, 313–14; medical expenditures and, 318, 321; mortality and, 316–17, 321; payment system for, 18; physician supply in, 13; technological change in, 309–14; technology regulation and, 308–9
Beta-blockers, 15, 392; in Alberta, 97–98; in Australia, 136–39, 149; in Belgium, 313; in England, 281; in Finland, 245; in France, 302; in Israel, 370, 371; in Italy, 334; in Japan, 170; in Ontario, 70; in Sweden, 220; in Switzerland, 351, 353; in the U.S., 26, 36–37, 38, 48
Blue Cross, 90, 97
Brianza, Italy, 334, 337
British Cardiac Intervention Society, 279
Budget caps, 121
Budget systems, global, 18 (see also Financing of care); in Belgium, 108, 307; in Denmark, 253–54, 265–66; in England, 271, 284; in France, 289–90, 291, 293, 299; in Italy, 347; in Sweden, 211, 213, 223, 225; in Switzerland, 354
Bureau of National Health Insurance (Taiwan), 196, 205
Bypass surgery (CABG), 15, 24, 385, 389, 391–92 (see also CABG); in Australia, 133; in England, 284; in Finland, 238; in Japan, 175; in Quebec, 76–77, 78; in the U.S., 24, 29, 31, 48, 49
Calcium antagonists, 263, 351, 353
Calcium channel blockers, 392; in Alberta (Can.), 97, 98; in Belgium, 313; in Finland, 245; in France, 302; in Israel, 370, 371; in Japan, 169; in the U.S., 37, 38, 48
California, 28, 29, 42, 49
Canada, 12, 14, 18, 115–16 (see also Alberta; Manitoba; Ontario; Quebec); fee-for-service in, 55, 60, 75, 90; IHD in, 156; insurance in, 13, 116; medical expenditures in, 58, 100–102, 106
Canadian Health Act, 55, 73
Canadian Institute for Health Information (CIHI), 59, 63
Cancer, 4, 6, 7, 41, 116, 396–97
300, 301; in Israel, 358–59, 365–66, 377; in Italy, 331–32; in Japan, 171, 175; laboratories for, 6, 12, 55, 309; in Sweden, 217; in Taiwan, 198, 199, 206; in the U.S., 29, 34, 48, 49, 50
Cardiac complications, 139–42
Cardiac surgery centers: in Belgium, 308, 309, 314, 318, 321; in Finland, 250
Cardiologists, 50, 176, 214, 258, 279, 367; in Belgium, 308; in England, 284; in Japan, 171; in Korea, 190
Cardiology, 283, 285, 309
Cardiothoracic surgery, 275, 283, 285
Cardiovascular disease, 184, 252, 330
CATH. See Angiography; Cardiac catheterization
Catheters, 293, 354
Cause of Death Data File (Taiwan), 194
Center for Interdisciplinary Study in Health Economics (CIES), 306–7, 309
Central Bureau of Statistics (Israel), 364
Charlson comorbidity index, 63, 65
Clinical Quality Improvement Network, 99
Clinical Standards Advisory Group (England), 270, 275–77, 278, 281, 283
Commissione Unica del Farmaco (Italy), 328
Commonwealth Department of Health (Australia), 123
Comorbidity, 63, 65, 94, 111, 143, 146, 364
Competition, 3, 13, 358; among managed-care plans, 27; in Belgium, 307; in Denmark, 256; in Finland, 238–39; in France, 294; in Italy, 328–29; in Korea, 187, 191; in Sweden, 225; in Switzerland, 348; in Taiwan, 197; in the U.S., 26–27
Congestive heart failure, 43–45, 373
Consumer information, 187, 191
Copayments, 11; in Australia, 133; in Belgium, 308; in England, 272; in France, 290, 291; in Italy, 325, 326; in Japan, 159; in Korea, 186; in Manitoba, 116; in Sweden, 211; in Switzerland, 346–47; in the U.S., 24
Coronary angiography. See Cardiac catheterization
Coronary arteriography, 353
Coronary artery procedures (CARPs), 113, 127, 130–32, 143, 151. See also Stenting
Costs (see also Financing of care; Medical expenditures): in Australia, 124; containment of, 102, 174, 308, 348, 359, 392; resource, 1
Danish Medical Association, 254, 257
Data limitations, 2, 177, 336
Death registry, 330. See also Mortality
Defibrillators, 36, 216, 259
Demographic data, 63–65
Denmark, AMI care in, 252–66; appropriateness of, 263–64; competition and, 13, 256; consequences of changes in, 264–65; financing of, 253–55, 265; high-tech, 259–61; incentives for technological change in, 253–58; low-tech, 263; medical expenditures and, 265; mortality and, 252, 264; physician supply in, 13, 258; regulation in, 12, 255–56; special interest groups in, 257; technological change in, 258–64; waiting lists and, 252, 256, 257, 259
Index

Diabetes, 4, 6
Diagnosis-related group (DRG) systems, 211, 225, 237, 308, 338; of Australia and Taiwan, 11; in Canada, 91; codes, 143–46, 286, 330; data, 295; in France, 302–3; in Italy, 326–27, 330, 337, 347; payments for, 49; in the U.S., 24, 36, 47
Diagnostic catheterization. See Cardiac catheterization
Diagnostic testing, 113
Diuretics, 263, 334, 351
Drugs, 151, 159 (see also Low-tech treatments; Thrombolytic drugs; and specific drugs); antiarrhythmics, 281, 351; in Australia, 124; in Belgium, 308, 318, 321; cardiac, 36, 70, 75, 79, 80, 83, 139; cholesterol-lowering, 7, 38, 49, 97, 136; costs in Taiwan, 201; in Denmark, 255, 263; and device regulation, 3–4, 293–94; expenditures, 92; in Finland, 245; in Italy, 327, 334; in Japan, 116, 159, 176; pharmaceuticals, 116, 214, 243; prescription, 24, 26, 272, 292; in Sweden, 211, 214
Drug therapies, 16, 28, 59–60, 75, 92–93, 97

Elderly patients, 34–36, 65–69, 375 (see also Age difference); in the U.S., 21, 29–30, 42, 47, 49
Electrocardiogram (ECG), 137, 259
England, AMI care in, 4, 6, 11, 16, 268–87, 393; appropriateness of, 281; consequences of changes in, 281; economy and, 272; expenditures for, 283–84; financing of, 18, 271–72; gatekeeper requirements in, 308; health outcomes in, 282–83; high-tech, 277–79; hospitals and, 13, 273–74; incentives for technological change in, 271–75; low-tech, 279–81; medical expenditures and, 283–84; mortality in, 270, 283, 284, 286; national expectations for, 274–75; reimbursement in, 391; technology regulation and, 12, 272–73
Equity, 380; of Canadian health care system, 106; in Finland, 239
European Commission, 256, 327
European Medical Agency (EMEA), 327
European Union, 325, 327
Expenditures. See Medical expenditures

Federal Law on Sickness and Accident Insurance (Switzerland), 345–46, 348
Federal Law on Sickness Insurance (Switzerland), 345, 347–48, 354
Fee-for-service system, 12, 390–91; in Belgium, 319; in Canada, 55, 60, 75, 90; in Denmark, 254; in France, 292; in Israel, 358; in Japan, 159; in Korea, 186; in Taiwan, 193, 196
Financing of care (see also Costs; Insurance; Medical expenditures; Reimbursement): in Canada, 59–60, 73, 75, 76, 89–92, 100–102; in Israel, 357–58; in the U.S., 22–25
Finland, AMI care in, 233–50, 252, 389; competition and, 238–39; consequences of changes in, 246–48; economy of, 237, 248; financing of, 18, 235–38; high-tech, 241–43; incentives for technological change in, 235–40; low-tech, 243–45; malpractice liability and, 239; MONICA study in, 240, 241, 245; mortality and, 133, 234, 246; municipalities of,
235–37; regulation and, 12, 238; regulation of physician supply and, 239–40; technological change in, 240–45

Food and Drug Administration (FDA), (U.S.), 25–26, 49, 256

France, AMI care in, 13, 289–303, 389; competition and, 294; drug and device regulation and, 293–94; financing of, 290–92; incentives for technological change in, 290–95; medical expenditures and, 289; MONICA Project in, 301; regional inequalities in, 293; regulation and, 12, 292–94; technological change and, 295–302

Fribourg, Switzerland, 344, 349, 352

Friuli region (Italy), 323, 330, 334, 337

Fukuoka Prefecture (Japan), 158, 164

Gallbladder disease, 4, 6

General practitioners, 253, 254, 268, 272, 292, 350

Geriatric medicine, 274. See also Elderly patients

Germany, 4, 156

Gruppo Italiano di Studi Emodinamici, 334

Health Care Insurance Plan, 89–92

Health Departments: England, 270; France, 292; Taiwan, 194; Western Australia, 126, 143

Health Insurance database (Belgium), 309

Health maintenance organizations (HMOs), 212

Health Ministry (Canada), 92

Health outcomes, 1, 5–8, 17, 72, 393 (see also Mortality); in Belgium, 306, 314–18; in England, 282–83; in Finland, 246–48; in Israel, 372–76, 380–82; in Italy, 336–37; in Japan, 171–74; in Manitoba, 113; regional differences in, 102, 336, 338; in Sweden, 220–22; in Taiwan, 200; in the U.S., 40–47

Heart disease, ischemic. See Ischemic heart disease

Heart failure, 16, 50, 145–46, 151, 220–22, 254; chronic, 163

Heart Plan 1993 (Denmark), 257–58

Heparin, 36–37, 170

High-tech treatments, 12, 14–15, 385, 389, 393 (see also Angioplasty; Bypass surgery; Cardiac catheterization); in Australia, 126–36; in Belgium, 310–13, 319; in Canada, 95–97, 108, 109–12; in Denmark, 259–61; in Finland, 241–43; in Israel, 364–69; in Italy, 330, 331–34, 337; in Japan, 166–69, 173; in Manitoba, 109–12; in Sweden, 216–20; in Switzerland, 349; in Taiwan, 199–200; in the U.S., 24, 29–36, 48, 49, 50

Hospital Claim File (Taiwan), 194–95, 198

Hospital Discharge Register (Finland), 234, 240–41, 243, 246

Hospital Episode Statistics (England), 270, 275–77, 281–82

Hospitalization Benefits Plan (Canada), 89

Hospitalization data, 94–95

Hospitals (see also Length of stay): in Belgium, 308; CCUs, 350, 358, 363; corporate, 191; in Denmark, 261–63; in Finland, 248; ownership of, 10, 13, 173, 197; private, 122–23, 173, 191, 229n. 18, 256, 291, 359; public, 121, 122, 256, 291, 293, 296, 347; reimbursement of, 24, 359; in Switzerland, 343–44, 347; teaching, 13, 106, 111; university, 235
Hypertension, 139, 314

ICD9 codes, 163, 198, 240, 258; in Belgium, 309; in Canada, 95, 108; in Israel, 356–57, 369, 381; in Italy, 330, 337

IHD. See Ischemic heart disease

Income, 3, 115, 116

Inpatient care, 2, 45–47, 211, 235, 259

Institute for Clinical Evaluative Sciences, 61

Institute for Pharmaco-Economics, 93

Insurance, 3, 13, 116, 291 (see also Financing of care; Payment systems; Reimbursement); in Australia, 123; in Belgium, 307–8; employer-provided, 24, 239; in England, 272; in Israel, 358; in Italy, 325, 347; in Japan, 158, 159; in Korea, 184; private, 11, 24, 75, 97, 150, 290; in Switzerland, 345–48, 353

Ischemic heart disease (IHD), 6–7, 84, 85, 163, 381; in Australia, 125, 131, 136, 139, 145–46, 150, 152; in Japan, 156; in Korea, 184; in Taiwan, 193, 205; in the U.S., 21, 25, 29, 42–45


Israel Central Bureau of Statistics, 356

Israel Medical Association, 362

Israel Society for the Prevention of Heart Attacks, 363

Italian Association of Hospital Cardiologists, 336

Italy, AMI care in, 323–39; appropriateness of, 334–36; competition and, 328–29; financing of, 324–25; health outcomes and, 336–37; high-tech, 331–34; incentives for technological change in, 324–30; low-tech, 334; medical expenditures and, 337; MONICA Project and, 339; mortality and, 330, 339; payment system and, 326–28, 336, 338; physician recruitment and, 329; regional differences in, 326, 336, 338; regulation and, 327–28; technological change in, 330–36

Japan, AMI care in, 12, 18, 156–80, 390; appropriateness of, 171; fee-for-service in, 173–74; health outcomes and, 171–74; high-tech, 166–69, 173; hospital ownership and, 13, 173; IHD in, 156; incentives for technological change in, 159–63; insurance for, 13, 158, 159; length of stay and, 173–74; low-tech, 169–71; medical expenditures and, 2, 173; mortality and, 163, 171–73, 176, 177; physician supply in, 13; reimbursement in, 159–60; technological change in, 163–71; thrombolytic drugs for, 164–65, 169–71

Korea, AMI care in, 12, 13, 184–91; financing of, 186–87; high-tech, 185, 188–91; hospitals in, 188, 191; incentives for technological change in, 186–88; incentives for technology use, 187–88; patient payments in, 11
Koseisho (Japanese Ministry of Health and Welfare), 159, 163

Length of stay (LOS), 376; in Canada, 99–100, 113; in European countries, 225, 248, 300, 318; in Japan, 173–74; in Taiwan, 203, 204–5; in the U.S., 34–36

Lidocaine, 37–38, 48, 97, 392

Life expectancy, 5, 115, 116, 252, 264

Lipid-lowering agents, 136, 149, 255, 256

Local Health Units (Italy), 325–26, 328

Lombardy, Italy, 334–36

Long-term care, 24, 208

Low-tech treatments (see also ACE inhibitors; Aspirin; Beta-blockers; Drugs; Thrombolytic drugs): in Australia, 136–39; in Belgium, 313–14; in Canada, 97–98, 112–13; changes in, 15–16, 390; in Denmark, 263; in England, 277–81, 286; in Finland, 243–45; in Israel, 370–71; in Italy, 330, 334, 338; in Japan, 169–71; in Sweden, 220; in Switzerland, 350–53; in Taiwan, 200; in the U.S., 49

Macroregulation, 12, 26, 384

Malpractice, 14, 27, 62, 214, 239, 329

Managed-care plans, 25, 26, 49, 50


McKinsey Global Research Institute, 4, 5–6

Med-Echo, 79, 80

Medicaid (Korea), 186

Medicaid (U.S.), 24, 26

Medical Benefits Regulations (Canada), 90

Medical expenditures, 2–5, 8, 18–19 (see also Costs; Financing of care; Insurance; Reimbursement); in Australia, 142–46; in Belgium, 318, 321; in Canada, 58, 100–102, 106; in Denmark, 265; in England, 283–84; in France, 289; in Israel, 356, 376–77; in Italy, 325, 337; in Japan, 2, 173; in Sweden, 223–25; in Switzerland, 343; in the U.S., 2, 22, 45–47, 124, 174

Medical Products Agency (Sweden), 212, 220

Medicare (Australia), 123

Medicare (U.S.), 12, 22–25, 26, 28, 47–48, 49, 116; reimbursement of, 50, 391

Medications. See Drugs; and specific medications

Medisave (Singapore), 11

Microregulation, 12–13, 348, 360, 384

Ministry of Budget (Italy), 326

Ministry of Education and Universities (Italy), 329–30

Ministry of Health (MOH): Denmark, 255; Israel, 357, 358–59, 362, 363, 364, 369, 372, 374, 380; Italy, 327, 328, 330, 338; Ontario (Can.), 60, 61

Ministry of Health and Welfare (Japan), 159, 163

Ministry of Health and Welfare (Korea), 185

MONICA Project, 6–8, 17, 136, 264–65, 385; in Australia, 122–25, 139; in Finland, 240, 241, 245; in France, 301; in Israel, 363, 373; in Italy, 330, 334; in Sweden, 216; in Switzerland, 344–45, 349
Mortality, 7, 17, 21, 393–94; in Alberta (Can.), 88, 99–100, 102–3; in Australia, 127, 136, 139; in Belgium, 316–17, 321; in Denmark, 252, 264; in England, 270, 283, 284, 286; in Finland, 133, 234, 246; in France, 289; in Israel, 356–57, 364, 372–74, 375, 381; in Italy, 336–37; in Japan, 163, 171–73, 176, 177; in Manitoba (Can.), 113; in Ontario (Can.), 55, 59, 66, 68–69; in Quebec (Can.), 80, 83–84, 86; in Sweden, 209, 216, 220; in Switzerland, 343; in Taiwan, 198, 200; in the U.S., 40, 41, 42, 49, 115

Mutuelles (France), 290–91

National Base for Public Hospitals (France), 296–99
National Board of Health (Denmark), 257, 258, 265, 266
National Board of Health and Welfare (Sweden), 208, 212, 215, 220, 227
National Corporation of Pharmacies (Sweden), 212, 220, 227
National Cost Base for Public Hospitals (France), 295–300
National Facility Survey (Japan), 160
National Health Care Evaluation Agency (France), 293
National Health Insurance, 359; Denmark, 253, 254, 256; Finland, 235; Korea, 186, 191; Taiwan, 193, 196–98, 198, 200, 205
National Health Service (England), 268, 270, 273, 274, 277, 284; data from, 281; hospitals of, 271, 275; incentives in, 284; patients of, 278
National Health System (Italy), 324–25, 328, 334
National Insurance Institute (Israel), 359
National Patient Register (Denmark), 258, 261
National Population Registry (Israel), 363–64
National Registry of Myocardial Infarction (U.S.), 28, 37
Netanyahu Commission of Inquiry (Israel), 359
Nitrates, 36–37, 97–98, 113, 136, 245, 351
Nitroglycerin, 170, 220
Nottingham Heart Attack Register (England), 270, 275–77, 281, 282
Nurses, 50, 97, 98
Nursing homes, 116, 208

Odense University Hospital (Denmark), 263
Office of Health Economics (England), 283
Ontario, AMI care in, 12, 55–56, 58–70, 91, 389; financing of, 59–60; mortality and, 55, 59, 66, 68–69; queue management in, 109; technological change and, 59–66; trends in health outcomes, 66–70
Ontario Drug Benefit (ODB) plan, 58, 61
Ontario Health Insurance Plan (OHIP), 58, 59
Open-heart surgery, 217
Organisation for Economic Cooperation and Development (OECD), 124, 268–69, 345
Oxford Record Linkage Study, 270, 275, 278, 282, 284, 287

Payment systems, 10, 18, 307 (see also Fee-for-service system; Reimbursement); in Australia, 124; Belgium, 309; capitation payments, 254; in England, 274; in Italy,
Perth, Australia, 122, 125–32, 146
Pharmaceuticals, 116, 214, 243. See also Drugs; Thrombolytic drugs
Physicians (see also Cardiologists; Specialists; Surgeons): general practitioners, 253, 254, 268, 272, 292, 350; primary, 25, 212, 328; reimbursement of, 60, 75, 86, 90, 97 (see also Fee-for-service system); services of, 4
Physician supply regulation, 13; in Australia, 121; in Canada, 62; in European countries, 239–40, 258, 274, 294–95; in Israel, 361; in Taiwan, 197
Poor people, in Canada, 116
Prevention, 7, 233
Primary physicians, 25, 212, 328
Private hospitals, 122–23, 173, 191, 229n. 18, 256, 291, 359
Provider decisions, 294
Public hospitals: in Australia, 121, 122; in Europe, 256, 291, 293, 296, 347
Quebec, AMI care in, 55–56, 72–86, 393–94; consequences of change in, 80–84; incentives for technological change in, 73–78; mortality and, 80, 83–84, 86
Queues, 109, 150, 210–11, 256, 257, 358. See also Waiting lists
Q-wave infarctions, 41, 102
Radiologists, 214, 392
Readmission, 124, 127, 150, 163, 313; in Australia, 132, 142, 145–46; in the U.S., 42–45, 49, 50
Recurrent AMI, 42–45, 127, 136, 139, 145–46, 151, 222
Régie de l’Assurance Maladie du Québec (RAMQ), 75, 79, 80, 83
Regional health authorities, 93
Regression models, 395–96
Regulation, 3, 10, 292–94, 357, 390; in Belgium, 308–9; in Canada, 60–62, 76, 92–93; of drugs and devices, 4, 293–94; in Israel, 360, 379; in Italy, 327–28; macro-, 12, 26, 384; micro-, 12–13, 348, 360, 384; in Taiwan, 197; in the U.S., 25–26
Regulatory Medical References, 294
Rehabilitation programs, 10, 371
Reimbursement, 10, 11, 174, 191 (see also Fee-for-service system;
Financing of care; Insurance; Medical expenditures; Payment systems); to hospitals, 24, 359; in Israel, 376–77, 379; in Italy, 337, 338, 347; in Japan, 159–60, 176; of physicians, 60, 75, 86, 90, 97
ReoPro (inhibitor), 360
Resource use, 8, 380; in Australia, 142–46; in Manitoba, 113–15
Revascularization, 15, 237, 238, 259, 385, 394 (see also Angioplasty; Bypass surgery; CABG; PTCA); in Australia, 127, 131–32, 136, 149, 150, 152; in Canada, 55, 59, 60, 70, 76, 80, 109, 113; in Denmark, 257; in England, 271; in Israel, 360, 367; in Italy, 336; in Japan, 75, 171; in Korea, 188; in the U.S., 34, 41, 50

Service d’Aide Médicale d’Urgence (SAMU), 291, 293

Sex differences, 42, 95–97; in Australia, 142, 146; in Belgium, 321; in Finland, 247–48; in Israel, 369, 374, 375–76, 382; in Italy, 332, 343, 347; in Manitoba (Can.), 109, 113

Sickness funds (see also Insurance): in France, 290–91, 292; in Israel, 348, 359–60, 361, 372, 379

Singapore, 11

Smoking, 7, 136

Social Health Insurance system (Sweden), 212

Social Insurance Institution (Finland), 235

Social Medical Treatment Survey (Japan), 163

Socioeconomic status, 397

Specialists, 25, 27, 62, 253, 361–62, 392 (see also Cardiologists; Surgeons); in Australia, 122, 123, 150

Statins, 97, 263, 381

Stenting, 34, 128, 133, 220, 284, 360 (see also PTCA); in Denmark, 255; in France, 293; in Israel, 367, 369, 381; in Korea, 186; in Switzerland, 349

Strasbourg, France, 301

Streptokinase, 37, 60, 98, 263, 294, 309, 390; in Israel, 360, 370; in Switzerland, 352, 354

Stroke, 7, 139, 396

Surgeons: cardiac, 190, 197, 258; cardiothoracic, 286; cardiovascular, 171, 176, 392

Surgery, 4, 217. See also Cardiac surgery centers; Cardiothoracic surgery

Sweden, AMI care in, 11, 13, 208–27, 392; consequences of changes in, 220–22; global budget system of, 18; high-tech, 216–20; incentives for technological change in, 209–15; low-tech, 220; malpractice in, 214; medical expenditures and, 223–25; MONICA Project in, 216; mortality and, 209, 216, 220; regulation in, 12, 212–13; system of, 208–9; technological change in, 215–20

Swedish National AMI Register, 215–16

Swedish National Inpatient Register, 215

Swedish National Registry for Cardiac Intensive Care (RIKS-HIA), 216

Swedish Register for Coronary Angioplasty, 216

Swiss Federal Social Insurance Office, 345

Switzerland, AMI care in, 343–55; change in, 348–53; competition in, 348; financing of, 345–48; high-tech, 349; incentives for technological change in, 345–48; incentives for technology use in, 348; insurance competition in, 13; low-tech, 350–53; medical expenditures and, 343; MONICA Project in, 344–45, 349

Taiwan, AMI care in, 193–206; consequences of, 200–205; DRG system of, 11; financing of, 196–97;
high-tech, 199–200; incentives for technological change in, 196–98; low-tech, 200; mortality and, 198, 200; technology regulation in, 197
Taxation, 235, 236, 253, 307
Tax revenues, 22, 73
Teaching hospitals, 13, 106, 111
Technological Change in Health Care (TECH) Global Research Network, 9, 15, 18, 395
Thrombolysis, 285, 314, 373
Thrombolytic drugs, 16, 390 (see also Streptokinase; and specific drugs); in Australia, 136–39, 149; in Belgium, 309, 312–13, 318, 321; in Canada, 59, 70, 97–98, 113; in Denmark, 261, 263; in England, 279–81; in Finland, 245; in France, 291, 293–94, 302; in Israel, 370, 371, 381–82; in Italy, 334; in Japan, 164–65, 169; in Korea, 175; in Sweden, 216, 220, 227; in Switzerland, 350–53; in Taiwan, 200, 206; in the U.S., 36–37, 38, 48, 49, 50
Ticino canton, Switzerland, 352–53
Tissue plasminogen activator (tPA), 37, 60, 263, 294, 309, 318, 390
Tort Act (Sweden), 214

United Kingdom, 270, 271, 275, 284. See also England
United States, AMI care in, 4, 6, 21–50, 327, 332, 390; appropriateness of, 38–39; competition in, 13, 26–27, 49; consequences of changes in, 40–47; drug use in, 170; effects of incentives, 47–51; expertise in, 38–40; financing of, 22–25; high-tech, 29–36, 389; IHD in, 156; incentives for technological change, 22–27; life expectancy in, 115; low-tech, 36–38; malpractice and, 14, 329; medical expenditures in, 2, 22, 45–47, 124, 174; mortality and, 40, 41, 42, 109, 115; ownership of hospitals in, 13; payment system of, 18; physician supply in, 13; price levels of, 393; regulation and, 12, 25–26, 212; specialization in, 27; technological change and, 28–40; uninsured in, 24; utilization review in, 308
Urokinase, 390
Utilization review, 308, 348

Varsinais-Suomi, Finland, 241–43
Vaud, Switzerland, 344, 349, 352
Victoria, Australia, 125–26, 132–36, 150

Waiting lists, 268, 308, 336 (see also Queues); in Canada, 94, 97, 106, 111; in Denmark, 252, 256, 257, 259
Western Australia, 133, 136, 150
Western Australia Minimum Data Set, 132
Western Australian Centre of Health Services Research database, 126
Winnipeg, Manitoba, 107–8, 111
World Health Organization (WHO), 6, 264, 363. See also MONICA Project